Sugammadex, neostigmine, and postoperative pulmonary complications: protocol of the SNaPP multicentre randomised controlled trial
Study context
- Population
- Patients aged ≥40 yr undergoing abdominal or thoracic surgeryplanned enrolment
- Participants
- 3,500 patients
- Planned comparison
- Sugammadex vs neostigmine for reversal of NMB
- Primary endpoint
- Composite of:
- PPCs (atelectasis, pneumonia, ARDS, aspiration pneumonitis, or a combination)
- Death
- Follow-up
- Until hospital discharge (or POD 7 if still in hospital)
Methodological detailsinternational, multicentre, 1:1 randomisation, stratified by centre, intention-to-treat, Sites in Australia, Aotearoa New Zealand, and Hong Kong, Recruitment 20 July 2023 to 3 July 2025; results anticipated in 2026
- International
- Multicentre
- 1:1 randomisation
- Stratified by centre
- Intention-to-treat
- Sites in Australia, Aotearoa New Zealand, and Hong Kong
- Recruitment 20 July 2023 to 3 July 2025; results anticipated in 2026
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Sugammadex, neostigmine, and postoperative pulmonary complications: protocol of the SNaPP multicentre randomised controlled trial. BJA Open. Published 10 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →